Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

Stock market today: S&P 500, Nasdaq soar as Senate vote lifts hopes for end to US shutdown

View original at finance.yahoo.com
Stock market today: S&P 500, Nasdaq soar as Senate vote lifts hopes for end to US shutdown Tech stocks led the market higher on Monday after the Senate took a big step toward ending the record-breaking government shutdown that has clouded the picture of the economy…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ozempic and Wegovy will fall to $350 per month from $1,000 and $1,350 per month through TrumpRX program

    80% confidence

  • There are clear signs an earnings recovery is underway that will fuel a stock rally next year

    80% confidence

  • A lot of liquidity pulled out of the market since August peaks, sentiment soured, and government shutdown brought malaise that turned market tenderness into vulnerability

    80% confidence

  • The extraordinary list of accomplishments achieved in the past few months tells the story of Venture Global's unwavering commitment to streamline high-impact execution in its growth to date

    80% confidence

  • US liquefaction capacity is expected to more than double by 2029

    80% confidence

  • S&P 500 will reach 7,500 by end of 2026

    80% confidence

  • North American LNG exports expected to more than double by 2029

    80% confidence

  • Zepbound and Orforglipron prices will fall to average of $346 per month from $1,086 through TrumpRX program

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Stock market today: S&P 500, Nasdaq soar as Senate vote lifts hopes for end to US shutdown — Source | Via News | ViaNews EU